About this Research Topic
The field of cancer research has been significantly focused on understanding the complex interplay between tumor mutations, immune evasion, and resistance to targeted therapies. Tumors are known to harbor a multitude of genetic alterations that not only drive their initiation, growth, and progression but also provide them with a selective advantage leading to immune evasion and therapy resistance. The tumor microenvironment further complicates this interaction by influencing the relationship between tumor cells and the immune system, thereby affecting treatment outcomes. Despite the current understanding of these processes, there are still gaps in knowledge, particularly in understanding how specific tumor mutations contribute to immune evasion and therapy resistance.
The primary aim of this research topic is to delve deeper into the intricate relationship between tumor mutations, immune evasion, and targeted therapy resistance. The goal is to understand how oncogenic mutations result in the production of neoantigens that can elicit an immune response and how tumor cells have evolved mechanisms to evade this immune surveillance. This includes the downregulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and recruitment of immunosuppressive cells. Furthermore, the research aims to investigate how these immune evasion mechanisms confer resistance to targeted therapies, which have revolutionized cancer treatment by selectively inhibiting key signaling pathways driving tumor growth.
The scope of this research topic is broad, focusing on the development of innovative therapeutic approaches that exploit the interplay between tumor mutations, immune evasion, and targeted therapy resistance. We welcome articles addressing, but not limited to, the following themes:
- The impact of tumor mutational processes on immune recognition and response.
- Overcoming therapy resistance driven by clonal evolution and tumor heterogeneity.
- Therapeutic modulation of the tumor immune microenvironment to enhance immunotherapy efficacy.
- The role of noncoding mutations in cancer progression and therapeutic response.
- Development of combination therapies targeting mutational drivers and the tumor microenvironment.
- Immunogenomic profiling of tumors to identify therapeutic vulnerabilities.
- The impact of chromosomal instability on tumor evolution and response to treatment.
- The role of tumor-associated neoantigens in shaping the immune response and guiding cancer therapy.
- The impact of metabolic alterations in tumor cells and the microenvironment on therapeutic strategies.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo), are out of scope for this section and will not be accepted as part of this Research Topic.
The primary aim of this research topic is to delve deeper into the intricate relationship between tumor mutations, immune evasion, and targeted therapy resistance. The goal is to understand how oncogenic mutations result in the production of neoantigens that can elicit an immune response and how tumor cells have evolved mechanisms to evade this immune surveillance. This includes the downregulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and recruitment of immunosuppressive cells. Furthermore, the research aims to investigate how these immune evasion mechanisms confer resistance to targeted therapies, which have revolutionized cancer treatment by selectively inhibiting key signaling pathways driving tumor growth.
The scope of this research topic is broad, focusing on the development of innovative therapeutic approaches that exploit the interplay between tumor mutations, immune evasion, and targeted therapy resistance. We welcome articles addressing, but not limited to, the following themes:
- The impact of tumor mutational processes on immune recognition and response.
- Overcoming therapy resistance driven by clonal evolution and tumor heterogeneity.
- Therapeutic modulation of the tumor immune microenvironment to enhance immunotherapy efficacy.
- The role of noncoding mutations in cancer progression and therapeutic response.
- Development of combination therapies targeting mutational drivers and the tumor microenvironment.
- Immunogenomic profiling of tumors to identify therapeutic vulnerabilities.
- The impact of chromosomal instability on tumor evolution and response to treatment.
- The role of tumor-associated neoantigens in shaping the immune response and guiding cancer therapy.
- The impact of metabolic alterations in tumor cells and the microenvironment on therapeutic strategies.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo), are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: tumor mutations, immune evasion, targeted therapy resistance, tumor heterogeneity, tumor microenvironment, cancer progression, tumor-associated neoantigens
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
